Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma Plc LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 8.65 0.00 07:32:51
Bid Price Offer Price High Price Low Price Open Price
8.20 8.80
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -1.57 -0.96 14
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 8.65 GBX

N4 Pharma (N4P) Latest News

More N4 Pharma News
N4 Pharma Investors    N4 Pharma Takeover Rumours

N4 Pharma (N4P) Discussions and Chat

N4 Pharma Forums and Chat

Date Time Title Posts
01/3/202121:04N4 Pharma3,390
11/2/202110:36N4 Pharma - Making good drugs better.4,389
14/9/202006:40N4P Covid-19 Wealth Warning108

Add a New Thread

N4 Pharma (N4P) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-03-04 16:22:038.75128,47411,247.77O
2021-03-04 16:15:348.503,000255.00O
2021-03-04 15:13:398.505,988508.98O
2021-03-04 14:59:498.7525,1462,200.28O
2021-03-04 14:57:538.7540,2983,528.05O
View all N4 Pharma trades in real-time

N4 Pharma (N4P) Top Chat Posts

N4 Pharma Daily Update: N4 Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker N4P. The last closing price for N4 Pharma was 8.65p.
N4 Pharma Plc has a 4 week average price of 8.02p and a 12 week average price of 7.25p.
The 1 year high share price is 15.50p while the 1 year low share price is currently 2.15p.
There are currently 156,080,349 shares in issue and the average daily traded volume is 919,793 shares. The market capitalisation of N4 Pharma Plc is £13,500,950.19.
finster007: Hey Chesty, jumped in today to see what happens here. N4P has always failed to hold a rise, tomorrow will be interesting....
viralspec: I don't think you will this time, the difference is Coronavirus. ______ RNS N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, is pleased to announce that the University of Queensland ("UQ") has been notified by the European Patent Office ("EPO") of its intention to grant a European Patent in relation to Nuvec(R) specifically in respect of its composition, particulate materials and methods for making the particulate materials (the "Patent"). N4 Pharma has the exclusive worldwide rights to Nuvec(R) for therapeutic uses in humans and animals. "The timing is especially relevant as we undertake our most comprehensive in vivo studies to date starting with Nuvec(R) loaded with the Coronavirus plasmid" _____ Valued currently at £20 Mill. SNG and NCYT ran to £100 Mill at the outset last year just on a sniff and in quick time. Worldwide patent here. European approval already. US coronavirus fund $ 1.3 Trillion.
professor_kemche: good to see so mant posite posts ,more positive posts the better as we go towards 1pDont want to see the short increase share price much morein my opinion ,so much potential at syme , d y o r
charlie88888: I do not understand people following shares on a daily, hourly, minutely etc basis.Every slight movement in the share price is dissected for reasons behind the movement!!!
pwhite73: You cannot talk a share price down or up. If it were so the market makers, brokers, banks etc would buy up all the share chat rooms and control what was said. N4P rather cleverly gave the impression they were closer to being able to freeze dry deliver the Pfizer vaccine. Its like me claiming I'm going to walk from here to the US. If I get to the end of my road I'm 200m closer but how long will it really take for me to walk to the US. That's where you are with this stock.
dplewis1: Why does he need to, this company proves time and time again that they will screw shareholders. It's a one trick pony that they will keep alive by decimating the share price every 6 months
jakleeds: 09/12/2020 8:10am UK Regulatory (RNS & others) TIDMN4P RNS Number : 0543I N4 Pharma PLC 09 December 2020 9 December 2020 This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 ("MAR"). In addition, market soundings (as defined in MAR) were taken in respect of the Placing with the result that certain persons became aware of inside information (as defined in MAR), as permitted by MAR. This inside information is set out in this announcement. Therefore, those persons that received inside information in a market sounding are no longer in possession of such inside information relating to the Company and its securities. N4 Pharma plc ("N4 Pharma" or the "Company") Placing to raise GBP2 million N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, is pleased to announce that it has raised GBP2 million (before expenses) through a placing of 25,000,000 new ordinary shares of 0.4p each in the Company (the "Placing Shares") at an issue price of 8p per Placing Share (the "Placing"). The Placing, which was significantly oversubscribed, was undertaken by share price Angel Corporate Finance LLP. The net proceeds of the Placing will be used for: -- the extension of the formulation and current stability work covering DNA and mRNA formulations; -- research on and evaluation of an additional asset to add to the Company portfolio; -- business development driven by study results pending over next six months; and -- ongoing working capital. Nigel Theobald, Chief Executive of N4 Pharma, commented: "We are delighted with the positive response to our recent formulation work. With vaccines and their delivery very much in the public consciousness we continue to grow our data package to present Nuvec(R) as a viable delivery technology solution to improve the delivery, storage and transportation of multiple existing and new vaccines. "Whilst we are well funded for all existing work streams these additional funds will enable us to plan for follow on studies and more product focussed experiments as we move towards collaborations." Application for Admission The Placing has been conducted utilising the Company's existing share authorities. Application has been made for the Placing Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will take place and that trading will commence on AIM at 8.00 a.m. on or around 14 December 2020. Once issued, the new Ordinary Shares will rank pari passu with the Company's existing ordinary shares. Total Voting Rights Following Admission, the enlarged issued share capital of the Company will comprise 181,080,349 Ordinary Shares of 0.4 pence each. The Company does not hold any ordinary shares in treasury. Consequently, 181,080,349 is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
master rsi: .... the share price
richjj: New to N4P but invested as see the potential . When do you think further presentations will follow from the company and how far do you feel the product will develop this year given the possible recent COVID vaccine intentions going into early next year. ?Additionally how far do you see the share price moving in this regard ? Thanks for your insights in advance.
jonc: !FOLLOWFEED Buying N4P might damage your wealth. However it is a Covid-19 outsider developing a novel delivery system for Covid-19 vaccines.. News is anticipated. Serious research is not required but would be welcomed. The N4P share price has retreated from highs of 32p and could retest on encouraging development news. Widows and Orphans not required. Ramping only please.
N4 Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
N4 Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210305 07:50:34